GRACE PATRICK P sold $101K of CHE

GRACE PATRICK P sold 190 shares of CHEMED CORP (CHE) at $532.00 ($0.10M total) on 2026-07-31.

Original reporting
SEC EDGAR · GRACE PATRICK P
Published Aug 3, 2026, 6:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 6:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CHE
Neutral
medium confidence
Mentioned
$CHE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CHENeutralLow
01

Why it matters

The only new information is the reported open-market sale of 190 shares at $532/share on July 31, with holdings after the sale of 3,533 shares.

02

Market read

Traders may monitor for clustering of insider sales, but this specific disclosure alone is unlikely to drive repricing without accompanying fundamental news.

03

What to watch

Insider sales are often tax- or diversification-driven; the article provides no context on motives, and the share count (190) is relatively small.

Relevance 4/10Novelty 4/10Timing: Form 4 filed Aug 3, after-hours/late day disclosure

Background

The article is an SEC Form 4 insider transaction disclosure for Chemed Corp (CHE) by director Grace Patrick P.

Company-level read

Ticker impact

$CHENeutralMedium confidence
Context

Chemed Corp director Grace Patrick P sold 190 shares in an open-market transaction at $532/share, totaling $101,080, per Form 4 filed today.

Expected impact

Likely limited near-term impact; treat as low-signal unless follow-on sales or broader insider activity emerges.

Evidence & confidence

The filing is a primary-source Form 4, but it reports a modest number of shares and does not include new company fundamentals or guidance.

Market effects

No clear sector read-through from a single, small insider sale.

None indicated.

None indicated.

Counterpoint

The absence of a disclosed 10b5-1 plan could be interpreted as discretionary selling, which some traders may view as mildly bearish.

Key entities

  • CHEMED CORP

    US-listed company whose director insider sale is disclosed via Form 4.

  • GRACE PATRICK P

    Director who sold 190 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CHEMedAI 9/10

Chemed 3Q 2026: Revenue $690.9M, EPS $5.45— 10-Q Summary

Chemed reported Q3 2026 revenue of $690.9M, up 10.6% YoY, with net income rising 11.5% to $71.6M and EPS increasing 22.2% to $5.45. Growth in VITAS and Roto-Rooter segments drove results, while higher fuel costs pressured margins. The company acquired RotoCo and other franchises, expanding its territories.

$CHEMed

What Chemed (CHE) Said on Its Q3 Earnings Call

Chemed reported Q3 earnings, with Roto-Rooter revenue up 7.5% but EBITDA down 2.5% due to higher costs. Commercial revenue grew 9% to $59.9M, while residential rose 5.2% to $158.8M. The company acquired California franchises for $62.5M, expecting $30M-$35M in 2027 revenue but less than $4M in EBITDA. Chemed repurchased 125,000 shares for $66M. Management expects 2026 EPS to meet or slightly exceed guidance.

$CHEMed

Chemed outlines 12- to 18-month integration timeline for $62.5M California Roto-Rooter franchise buyback while expecting 2026 EPS at or slightly above prior high end (NYSE:CHE)

Chemed (CHE) announced a 12- to 18-month integration timeline for its $62.5M California Roto-Rooter franchise buyback. CEO Kevin McNamara reported VITAS revenue grew 12.2% year-over-year, driven by ADC growth and cost containment. The company expects 2026 EPS to be at or slightly above the prior high end.

$CHEHighAI 8/10

Chemed (CHE) Q3 2026 Earnings Call Transcript

Chemed (CHE) reported Q3 2026 earnings with total revenue up 10.6% and adjusted EPS up 28.1% YoY. VITAS saw 12.2% revenue growth, while Roto Rooter grew 7.5%. Roto Rooter's margins declined due to higher marketing costs and fuel expenses, but acquisitions are expected to drive long-term growth. The company has $229M in cash flow from operations, enabling strategic acquisitions and share repurchases.

$CHEHighAI 8/10

Why is Chemed stock surging today?

Chemed (CHE) stock rose 9.2% after Q3 earnings beat estimates, with adjusted EPS of $6.75 and revenue of $690.9M. VITAS hospice division showed strong growth. Jefferies upgraded the stock to Buy, raising its price target to $620. Bank of America also increased its target to $555. The stock hit a 52-week high.